Modified CAR-T cell therapy for relapsed B-cell lymphoma
Treatments studied
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This study tests a new kind of CAR-T cell therapy for people with certain types of B-cell lymphoma that have come back or not improved after standard treatments. The CAR-T cells have been modified to turn off two genes (BCOR and ZC3H12) to make them work better against the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 70 years old.
- You need a type of B-cell lymphoma (like DLBCL, follicular lymphoma, or mantle cell lymphoma) that has come back or hasn't responded to standard treatments.
- You should have had at least two previous treatments, including an anti-CD20 antibody (like rituximab) and chemotherapy. If you have mantle cell lymphoma, you also need a BTK inhibitor (like ibrutinib).
- Your cancer cells must be CD19-positive, meaning they have a certain protein on their surface that the treatment targets.
- You must not have had CAR-T cell therapy before.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new type of immune cell therapy (CAR-T cells) that targets a protein called CD19 on your lymphoma cells. It's for people whose B-cell lymphoma has returned or not responded to standard treatments.
This study tests a new type of CAR T cell therapy that targets the CD20 protein on B-cell lymphoma cells. It is for people with certain types of B-cell lymphoma that have not responded to at least two previous treatments and who cannot use or have already tried the approved CD19 CAR T therapy.
This trial tests a new type of CAR-T cell therapy for people with certain B-cell lymphomas that have come back or not responded to treatment. The CAR-T cells are made from a donor and are genetically edited to possibly work better and last longer.
This trial tests a new treatment made from your own immune cells (gamma-delta T cells) that are engineered to find and kill CD19-positive lymphoma cells. It is for people with B-cell non-Hodgkin lymphoma whose cancer has not responded to or has returned after at least two standard treatments.
This trial tests a new type of CAR-T cell therapy that is engineered to be more effective against a specific kind of leukemia (B-ALL) that has returned or not responded to treatment. The therapy uses a patient's own immune cells to target and destroy cancer cells.
This Phase 1/2 trial studies an “off-the-shelf” (allogeneic) immune-cell therapy that targets CD19, a marker on many B-cell lymphomas. It’s for adults whose lymphoma has come back or didn’t respond to prior treatment, aiming to shrink tumors and improve outcomes.
Hear when a new Lymphoma, B-Cell trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.